DOUBLE-BLIND LEVAMISOLE TRIAL IN RESECTABLE LUNG CANCER

The third interim analysis of a prospective double-blind placebo-controlled trial with levamisole as an adjunct to surgery in resectable primary lung carcinoma is reported. The data show that a beneficial effect is clearly present in patients who weigh 70 kg or less but not in others; therefore, it...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 1976-01, Vol.277 (1), p.260-268
Main Author: Amery, Willem K.
Format: Article
Language:English
Subjects:
Adult
Aged
Belgium
Chemical Phenomena
Chemistry
Clinical Trials as Topic
Female
Humans
Levamisole - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - surgery
Male
Middle Aged
Placebos
Prospective Studies
Skin Tests
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4070-6217675a5db8fad6ab6fc5d2d9f7737692b6d25e3cdce137945e0411fed48c5f3
cites
container_end_page 268
container_issue 1
container_start_page 260
container_title Annals of the New York Academy of Sciences
container_volume 277
creator Amery, Willem K.
description The third interim analysis of a prospective double-blind placebo-controlled trial with levamisole as an adjunct to surgery in resectable primary lung carcinoma is reported. The data show that a beneficial effect is clearly present in patients who weigh 70 kg or less but not in others; therefore, it would seem advisable to prescribe levamisole at a dosage of 2.5 mg/kg/day. In the adequately dosed patients, an almost complete elimination of distant metastases is found. The levamisole effect also seem more pronounced in patients who have a heavier tumor load at operation. The rationale for starting levamisole before surgery and for continuing thereafter is briefly discussed.
doi_str_mv 10.1111/j.1749-6632.1976.tb41704.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_83696827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>83696827</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4070-6217675a5db8fad6ab6fc5d2d9f7737692b6d25e3cdce137945e0411fed48c5f3</originalsourceid><addsrcrecordid>eNqVkMtOg0AUhifGW62-gQviwh04N2bAjaEUEYM0Kb3E1QSYIaG2tjJtbN9eCE33ns1Z_P_5TvIB8ICghZp5WliIU9dkjGALuZxZ25wiDqm1PwO9U3QOehBybjouJtfgRusFhAg7lF-BS-4S6qAe4MPRdBAH5iCOkqERBzPvI0pHcWBMxpEXG1FijIM08CdeUzLiaRIavpf4wfgWXJTZUqu74-6D6Wsw8d_MeBRGvhebBYUcmgwjzrid2TJ3ykyyLGdlYUss3ZJzwpmLcyaxrUghC4UId6mtIEWoVJI6hV2SPnjsuJt6_bNTeitWlS7Ucpl9q_VOC4cwlzmYN8XnrljUa61rVYpNXa2y-iAQFK00sRCtGdGaEa00cZQm9s3x_fHLLl8peTrtLDXxSxf_Vkt1-AdYJJ9eihlsCGZHqPRW7U-ErP4SrPFgi3kSitk8TN_nyVBA8gcPDIXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>83696827</pqid></control><display><type>article</type><title>DOUBLE-BLIND LEVAMISOLE TRIAL IN RESECTABLE LUNG CANCER</title><source>Wiley-Blackwell Journals</source><creator>Amery, Willem K.</creator><creatorcontrib>Amery, Willem K.</creatorcontrib><description>The third interim analysis of a prospective double-blind placebo-controlled trial with levamisole as an adjunct to surgery in resectable primary lung carcinoma is reported. The data show that a beneficial effect is clearly present in patients who weigh 70 kg or less but not in others; therefore, it would seem advisable to prescribe levamisole at a dosage of 2.5 mg/kg/day. In the adequately dosed patients, an almost complete elimination of distant metastases is found. The levamisole effect also seem more pronounced in patients who have a heavier tumor load at operation. The rationale for starting levamisole before surgery and for continuing thereafter is briefly discussed.</description><identifier>ISSN: 0077-8923</identifier><identifier>EISSN: 1749-6632</identifier><identifier>DOI: 10.1111/j.1749-6632.1976.tb41704.x</identifier><identifier>PMID: 793481</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Belgium ; Chemical Phenomena ; Chemistry ; Clinical Trials as Topic ; Female ; Humans ; Levamisole - therapeutic use ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - surgery ; Male ; Middle Aged ; Placebos ; Prospective Studies ; Skin Tests</subject><ispartof>Annals of the New York Academy of Sciences, 1976-01, Vol.277 (1), p.260-268</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4070-6217675a5db8fad6ab6fc5d2d9f7737692b6d25e3cdce137945e0411fed48c5f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1749-6632.1976.tb41704.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1749-6632.1976.tb41704.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27924,27925,46049,46473</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/793481$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Amery, Willem K.</creatorcontrib><title>DOUBLE-BLIND LEVAMISOLE TRIAL IN RESECTABLE LUNG CANCER</title><title>Annals of the New York Academy of Sciences</title><addtitle>Ann N Y Acad Sci</addtitle><description>The third interim analysis of a prospective double-blind placebo-controlled trial with levamisole as an adjunct to surgery in resectable primary lung carcinoma is reported. The data show that a beneficial effect is clearly present in patients who weigh 70 kg or less but not in others; therefore, it would seem advisable to prescribe levamisole at a dosage of 2.5 mg/kg/day. In the adequately dosed patients, an almost complete elimination of distant metastases is found. The levamisole effect also seem more pronounced in patients who have a heavier tumor load at operation. The rationale for starting levamisole before surgery and for continuing thereafter is briefly discussed.</description><subject>Adult</subject><subject>Aged</subject><subject>Belgium</subject><subject>Chemical Phenomena</subject><subject>Chemistry</subject><subject>Clinical Trials as Topic</subject><subject>Female</subject><subject>Humans</subject><subject>Levamisole - therapeutic use</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - surgery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Placebos</subject><subject>Prospective Studies</subject><subject>Skin Tests</subject><issn>0077-8923</issn><issn>1749-6632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1976</creationdate><recordtype>article</recordtype><recordid>eNqVkMtOg0AUhifGW62-gQviwh04N2bAjaEUEYM0Kb3E1QSYIaG2tjJtbN9eCE33ns1Z_P_5TvIB8ICghZp5WliIU9dkjGALuZxZ25wiDqm1PwO9U3QOehBybjouJtfgRusFhAg7lF-BS-4S6qAe4MPRdBAH5iCOkqERBzPvI0pHcWBMxpEXG1FijIM08CdeUzLiaRIavpf4wfgWXJTZUqu74-6D6Wsw8d_MeBRGvhebBYUcmgwjzrid2TJ3ykyyLGdlYUss3ZJzwpmLcyaxrUghC4UId6mtIEWoVJI6hV2SPnjsuJt6_bNTeitWlS7Ucpl9q_VOC4cwlzmYN8XnrljUa61rVYpNXa2y-iAQFK00sRCtGdGaEa00cZQm9s3x_fHLLl8peTrtLDXxSxf_Vkt1-AdYJJ9eihlsCGZHqPRW7U-ErP4SrPFgi3kSitk8TN_nyVBA8gcPDIXw</recordid><startdate>19760101</startdate><enddate>19760101</enddate><creator>Amery, Willem K.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19760101</creationdate><title>DOUBLE-BLIND LEVAMISOLE TRIAL IN RESECTABLE LUNG CANCER</title><author>Amery, Willem K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4070-6217675a5db8fad6ab6fc5d2d9f7737692b6d25e3cdce137945e0411fed48c5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1976</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Belgium</topic><topic>Chemical Phenomena</topic><topic>Chemistry</topic><topic>Clinical Trials as Topic</topic><topic>Female</topic><topic>Humans</topic><topic>Levamisole - therapeutic use</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - surgery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Placebos</topic><topic>Prospective Studies</topic><topic>Skin Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amery, Willem K.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amery, Willem K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DOUBLE-BLIND LEVAMISOLE TRIAL IN RESECTABLE LUNG CANCER</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><addtitle>Ann N Y Acad Sci</addtitle><date>1976-01-01</date><risdate>1976</risdate><volume>277</volume><issue>1</issue><spage>260</spage><epage>268</epage><pages>260-268</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><abstract>The third interim analysis of a prospective double-blind placebo-controlled trial with levamisole as an adjunct to surgery in resectable primary lung carcinoma is reported. The data show that a beneficial effect is clearly present in patients who weigh 70 kg or less but not in others; therefore, it would seem advisable to prescribe levamisole at a dosage of 2.5 mg/kg/day. In the adequately dosed patients, an almost complete elimination of distant metastases is found. The levamisole effect also seem more pronounced in patients who have a heavier tumor load at operation. The rationale for starting levamisole before surgery and for continuing thereafter is briefly discussed.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>793481</pmid><doi>10.1111/j.1749-6632.1976.tb41704.x</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0077-8923
ispartof Annals of the New York Academy of Sciences, 1976-01, Vol.277 (1), p.260-268
issn 0077-8923
1749-6632
language eng
recordid cdi_proquest_miscellaneous_83696827
source Wiley-Blackwell Journals
subjects Adult
Aged
Belgium
Chemical Phenomena
Chemistry
Clinical Trials as Topic
Female
Humans
Levamisole - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - surgery
Male
Middle Aged
Placebos
Prospective Studies
Skin Tests
title DOUBLE-BLIND LEVAMISOLE TRIAL IN RESECTABLE LUNG CANCER
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A55%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DOUBLE-BLIND%20LEVAMISOLE%20TRIAL%20IN%20RESECTABLE%20LUNG%20CANCER&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=Amery,%20Willem%20K.&rft.date=1976-01-01&rft.volume=277&rft.issue=1&rft.spage=260&rft.epage=268&rft.pages=260-268&rft.issn=0077-8923&rft.eissn=1749-6632&rft_id=info:doi/10.1111/j.1749-6632.1976.tb41704.x&rft_dat=%3Cproquest_cross%3E83696827%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4070-6217675a5db8fad6ab6fc5d2d9f7737692b6d25e3cdce137945e0411fed48c5f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=83696827&rft_id=info:pmid/793481&rfr_iscdi=true